KR101762966B1 - 항체 제제 - Google Patents

항체 제제 Download PDF

Info

Publication number
KR101762966B1
KR101762966B1 KR1020117015821A KR20117015821A KR101762966B1 KR 101762966 B1 KR101762966 B1 KR 101762966B1 KR 1020117015821 A KR1020117015821 A KR 1020117015821A KR 20117015821 A KR20117015821 A KR 20117015821A KR 101762966 B1 KR101762966 B1 KR 101762966B1
Authority
KR
South Korea
Prior art keywords
formulation
antibody
acz885
chain variable
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020117015821A
Other languages
English (en)
Korean (ko)
Other versions
KR20120009421A (ko
Inventor
요아힘 몸
한스-요아힘 발니
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40637230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101762966(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20120009421A publication Critical patent/KR20120009421A/ko
Application granted granted Critical
Publication of KR101762966B1 publication Critical patent/KR101762966B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020117015821A 2008-12-10 2009-12-09 항체 제제 Active KR101762966B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08170884.4 2008-12-10
EP08170884A EP2196476A1 (en) 2008-12-10 2008-12-10 Antibody formulation
PCT/EP2009/066675 WO2010066762A1 (en) 2008-12-10 2009-12-09 Antibody formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177009939A Division KR20170044211A (ko) 2008-12-10 2009-12-09 항체 제제

Publications (2)

Publication Number Publication Date
KR20120009421A KR20120009421A (ko) 2012-01-31
KR101762966B1 true KR101762966B1 (ko) 2017-07-31

Family

ID=40637230

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020117015821A Active KR101762966B1 (ko) 2008-12-10 2009-12-09 항체 제제
KR1020177009939A Ceased KR20170044211A (ko) 2008-12-10 2009-12-09 항체 제제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177009939A Ceased KR20170044211A (ko) 2008-12-10 2009-12-09 항체 제제

Country Status (31)

Country Link
US (3) US20110236398A1 (https=)
EP (4) EP2196476A1 (https=)
JP (6) JP6143416B2 (https=)
KR (2) KR101762966B1 (https=)
CN (3) CN104399076B (https=)
AU (1) AU2009324371B2 (https=)
BR (1) BRPI0922730A2 (https=)
CA (1) CA2745938C (https=)
CL (1) CL2011001406A1 (https=)
CO (1) CO6361952A2 (https=)
CY (2) CY1117735T1 (https=)
DK (2) DK2376533T3 (https=)
EC (1) ECSP11011192A (https=)
ES (2) ES2900624T3 (https=)
HR (2) HRP20211899T1 (https=)
HU (2) HUE028408T2 (https=)
IL (3) IL264316B2 (https=)
LT (1) LT3072906T (https=)
MA (1) MA33023B1 (https=)
MX (1) MX2011006242A (https=)
MY (2) MY166050A (https=)
NZ (1) NZ592918A (https=)
PE (1) PE20120342A1 (https=)
PL (2) PL3072906T3 (https=)
PT (2) PT2376533T (https=)
RU (2) RU2745601C2 (https=)
SI (2) SI2376533T1 (https=)
SM (1) SMT201600222B (https=)
TN (1) TN2011000229A1 (https=)
WO (1) WO2010066762A1 (https=)
ZA (1) ZA201103362B (https=)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
EP3409289B1 (en) 2010-02-26 2020-09-30 Novo Nordisk A/S Stable antibody containing compositions
PT3345615T (pt) 2010-03-01 2020-01-17 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
RU2012153786A (ru) 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
AR082319A1 (es) * 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US20120076779A1 (en) 2010-09-17 2012-03-29 Baxter Healthcare S.A. STABILIZATION OF IMMUNOGLOBULINS AND OTHER PROTEINS THROUGH AQUEOUS FORMULATIONS WITH SODIUM CHLORIDE AT WEAK ACIDIC TO NEUTRAL ph
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
TWI719112B (zh) 2011-03-16 2021-02-21 賽諾菲公司 雙重ｖ區類抗體蛋白質之用途
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
FI123630B (fi) 2011-10-24 2013-08-30 Teknologian Tutkimuskeskus Vtt Menetelmä NFC-kalvojen valmistamiseksi alustoille
US20140348848A1 (en) 2011-12-02 2014-11-27 Dhananjay Kaul Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
JP6345123B2 (ja) * 2012-02-16 2018-06-20 サンタラス， インコーポレイテッド 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物
EP3539374A1 (en) * 2012-03-16 2019-09-18 Regeneron Pharmaceuticals, Inc. Non-human animals expressing ph-sensitive immunoglobulin sequences
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
UA115789C2 (uk) * 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
MA37946B1 (fr) * 2012-09-20 2018-09-28 Morphosys Ag Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde
JP2016502526A (ja) * 2012-11-16 2016-01-28 ノバルティス アーゲー 末梢動脈疾患を処置するためのＩＬ−１β結合抗体の使用
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
TW201513882A (zh) 2013-03-15 2015-04-16 Bayer Healthcare Llc 抗－催乳激素受體抗體調配物
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015181757A1 (en) * 2014-05-28 2015-12-03 Nono Inc. Lyophilized formulation of tat-nr2b9c with acetylation scavenger
CA2959571A1 (en) * 2014-09-03 2016-03-10 Medimmune Limited Stable anti-il-4r-alpha antibody formulation
CA2966905A1 (en) 2014-11-12 2016-05-19 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
LT3386541T (lt) 2015-12-07 2020-10-26 Merck Patent Gmbh Vandeninė farmacinė kompozicija, apimanti anti-pd-1 antikūną avelumabą
WO2018002031A1 (en) * 2016-06-27 2018-01-04 Morphosys Ag Anti-cd19 antibody formulations
JP2019521161A (ja) * 2016-07-21 2019-07-25 ノバルティス アーゲー 肺サルコイドーシスの症状を治療するまたは軽減するためのＩＬ−１β結合抗体カナキヌマブの使用
KR102546471B1 (ko) * 2016-09-27 2023-06-21 프레제니우스 카비 도이치란트 게엠베하 액상의 약학 조성물
TWI780082B (zh) 2016-11-18 2022-10-11 日商安斯泰來製藥股份有限公司 新穎抗人類ＭＵＣ１抗體Ｆａｂ片段
CA3061874A1 (en) * 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
TWI795415B (zh) * 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
CN111315412A (zh) * 2017-09-13 2020-06-19 诺华股份有限公司 Il-1b结合抗体用于治疗酒精性肝炎的用途
WO2019180261A1 (en) * 2018-03-23 2019-09-26 AbbVie Deutschland GmbH & Co. KG Stable aqueous anti-tau antibody formulations
BR112020023420A8 (pt) 2018-05-17 2022-07-05 Astellas Pharma Inc Complexo tendo fragmento fab de anticorpo anti-muc1 humano, peptídeo ligador e/ou ligante
SG11202103670XA (en) * 2018-10-10 2021-05-28 Astellas Pharma Inc Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
CN120241997A (zh) * 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
CN113967195A (zh) * 2020-07-22 2022-01-25 三生国健药业（上海）股份有限公司 抗her2/pd1双特异性抗体冻干制剂及其制备方法
EP4268803A4 (en) * 2020-12-22 2025-04-16 Bio-Thera Solutions, Ltd. Stable antibody preparation, preparation method for same, and applications thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016436A2 (en) * 2000-08-22 2002-02-28 Novartis Ag ANTIBODIES TO HUMAN IL-1$g(b)
US20040038878A1 (en) * 2000-08-04 2004-02-26 Masahiko Tanikawa Injectable protein formulations

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
PE64396A1 (es) 1995-01-23 1997-01-28 Hoffmann La Roche Proteina accesoria del receptor de la interleucina 1
ES2434840T3 (es) 1995-07-27 2013-12-17 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
KR100919593B1 (ko) 2000-06-29 2009-09-29 아보트 러보러터리즈 이중 특이성 항체 및 이의 제조 방법 및 이를 포함하는 조성물
IL161677A0 (en) * 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
MXPA05010555A (es) * 2003-04-04 2006-03-09 Genentech Inc Formulaciones de proteina y anticuerpo de alta concentracion.
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
PA8661401A1 (es) * 2005-01-28 2006-09-08 Wyeth Corp Formulaciones del liquido polipeptido estabilizado
ES2569409T3 (es) * 2005-03-08 2016-05-10 Pfizer Products Inc. Composiciones de anticuerpo anti-CTLA-4
EP1888637A2 (en) * 2005-05-19 2008-02-20 Amgen Inc. Compositions and methods for increasing the stability of antibodies
PL1940465T3 (pl) 2005-10-26 2013-01-31 Novartis Ag Nowe zastosowanie przeciwciał anty-IL-1beta
CN201044845Y (zh) * 2006-10-28 2008-04-09 李开元 自动注射器
CL2007003583A1 (es) * 2006-12-11 2008-07-18 Hoffmann La Roche Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer.
EP2136839A4 (en) * 2007-03-22 2010-04-07 Imclone Llc STABLE ANTIBODY FORMULATIONS
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
WO2010100179A2 (en) 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040038878A1 (en) * 2000-08-04 2004-02-26 Masahiko Tanikawa Injectable protein formulations
WO2002016436A2 (en) * 2000-08-22 2002-02-28 Novartis Ag ANTIBODIES TO HUMAN IL-1$g(b)

Also Published As

Publication number Publication date
SI2376533T1 (sl) 2016-07-29
DK2376533T3 (en) 2016-06-27
LT3072906T (lt) 2021-12-27
IL276622A (en) 2020-09-30
MY166050A (en) 2018-05-22
RU2563179C2 (ru) 2015-09-20
BRPI0922730A2 (en) 2018-11-06
RU2015132431A3 (https=) 2018-12-24
JP2023109938A (ja) 2023-08-08
EP2376533A1 (en) 2011-10-19
IL212922B (en) 2019-02-28
MX2011006242A (es) 2011-06-24
HRP20160754T1 (hr) 2016-08-12
CN104399076A (zh) 2015-03-11
US8623367B2 (en) 2014-01-07
PL3072906T3 (pl) 2022-01-24
DK3072906T3 (da) 2021-12-13
IL264316A (en) 2019-02-28
ECSP11011192A (es) 2011-08-31
US20200384108A1 (en) 2020-12-10
HRP20211899T1 (hr) 2022-03-04
EP2196476A1 (en) 2010-06-16
IL264316B1 (en) 2023-09-01
ZA201103362B (en) 2012-01-25
EP2376533B1 (en) 2016-03-30
MY157772A (en) 2016-07-29
NZ592918A (en) 2012-12-21
IL212922A0 (en) 2011-07-31
RU2015132431A (ru) 2018-12-24
RU2011127913A (ru) 2013-01-20
SMT201600222B (it) 2016-08-31
HUE028408T2 (en) 2016-12-28
RU2745601C2 (ru) 2021-03-29
JP2012511540A (ja) 2012-05-24
PT3072906T (pt) 2021-12-14
CY1117735T1 (el) 2017-05-17
JP7286595B2 (ja) 2023-06-05
SI3072906T1 (sl) 2022-01-31
JP2020203889A (ja) 2020-12-24
CO6361952A2 (es) 2012-01-20
CN114225022A (zh) 2022-03-25
JP2018168158A (ja) 2018-11-01
HK1159130A1 (zh) 2012-07-27
WO2010066762A1 (en) 2010-06-17
CN102245639A (zh) 2011-11-16
IL264316B2 (en) 2024-01-01
PT2376533T (pt) 2016-07-13
HUE056626T2 (hu) 2022-02-28
AU2009324371B2 (en) 2013-10-10
JP6143416B2 (ja) 2017-06-07
CL2011001406A1 (es) 2012-03-30
TN2011000229A1 (en) 2012-12-17
CN102245639B (zh) 2014-12-24
CN104399076B (zh) 2021-09-14
PE20120342A1 (es) 2012-04-24
JP2015231997A (ja) 2015-12-24
ES2900624T3 (es) 2022-03-17
JP2026021446A (ja) 2026-02-10
PL2376533T3 (pl) 2016-09-30
EP3072906A1 (en) 2016-09-28
US20120315285A1 (en) 2012-12-13
CA2745938A1 (en) 2010-06-17
EP3792282A1 (en) 2021-03-17
EP3072906B1 (en) 2021-09-08
KR20120009421A (ko) 2012-01-31
US20110236398A1 (en) 2011-09-29
MA33023B1 (fr) 2012-02-01
AU2009324371A1 (en) 2011-06-23
CA2745938C (en) 2018-04-24
KR20170044211A (ko) 2017-04-24
ES2579835T3 (es) 2016-08-17
CY1124844T1 (el) 2022-11-25

Similar Documents

Publication Publication Date Title
KR101762966B1 (ko) 항체 제제
DE69230789T2 (de) Methoden zur behandlung von durch den tumor nekrose faktor ausgelösten krankheiten
CN106061468B (zh) 包含TNFR和Fc区的融合蛋白的液体制剂
US20030211103A1 (en) Use of primate IFN-gamma binding molecules
HK40041917A (en) Antibody formulation
HK1159130B (en) Antibody formulation

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20110708

Patent event code: PA01051R01D

Comment text: International Patent Application

AMND Amendment
PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20141208

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160301

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170112

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160301

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20170412

PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20170112

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20160901

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20141208

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20111222

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20170427

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20170412

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20170112

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20160901

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20141208

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20111222

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20170724

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20170724

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20200630

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20200630

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20210629

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20210629

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20220630

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20220630

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20230628

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20240627

Start annual number: 8

End annual number: 8